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405 citations. Two reviewers independently examined each citation and abstract. We
conducted three levels of review resulting in 94 papers for full review. Data were
analyzed using qualitative and quantitative methods, including a meta-analysis using 
a random effects model (REM) and Mantel-Haenszel (MH) summary estimate.
RESULTS: The most common research design involved randomized controlled trials
(RCTs) (60/94, 64%). Seventy-two (77%) studies involved interventions that sought
to directly improve medication compliance, 12 (13%) had to do with interventions to
improve compliance through a multidisciplinary process, 5 (5%) involved interven-
tions to indirectly improve compliance through changing physician practice, and 5 
(5%) were other types. Thirteen studies (14%) involved the use of a theoretical 
framework to guide the research. A meta-analysis was conducted of RCTs of educa-
tional interventions, (N  6). The REM showed a trend toward statistical signiﬁ cance
with a risk ratio of 0.83 for non-compliance (95% CI: 0.68 1.00, p  0.05). The
MH summary estimate was statistically signiﬁ cant with a risk ratio of 0.83 for non-
compliance (95% CI: 0.75–0.92, p  0.00), favoring patients who received educational 
interventions to improve compliance. However, the X2 test for heterogeneity was sig-
niﬁ cant; p  0.020 and p  0.016 respectively. CONCLUSIONS: Our analysis indi-
cated that most interventions focused on directly improving medication compliance. 
The meta-analysis illustrated educational strategies provide a signiﬁ cant beneﬁ t in 
reducing non-compliance in patients using antihypertensives. The small sample size 
may have contributed to the observed heterogeneity and require additional investiga-
tion. Our ﬁ ndings have implications for designing future research and implementing 
educational interventions.
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MEDICATION ADHERENCE AND CARDIOVASCULAR DISEASE-RELATED
HEALTH CARE RESOURCE UTILIZATION AMONG PATIENTS TREATED
WITH FIXED DOSE COMBINATION VERSUS MULTI-PILL COMBINATION 
THERAPIES AMONG PATIENTS WITH DYSLIPIDEMIA IN A MANAGED 
CARE POPULATION
Balu S1, Simko RJ1, Webb SF1, Quimbo R2, Cziraky MJ2
1Abbott Laboratories, Abbott Park, IL, USA, 2HealthCore, Inc., Wilmington, DE, USA
OBJECTIVES: Evaluate the impact of medication adherence on total health care
resource utilization (THR) among dyslipidemia patients initiating ﬁ xed dose combina-
tion (FDC) therapy versus multi-pill combination (MPC) therapies in a managed care
population. METHODS: Using claims data from the HealthCore Integrated Research 
Database, study patients q18 years were identiﬁ ed as newly-initiating on FDC 
[Advicor: niacin extended release (NER)  lovastatin] or MPC’s [simvastatin  NER
(NER/S), lovastatin  NER (NER/L)] between January 1, 2000-June 30, 2006 [index 
date], with a minimum 6 months pre- and 12 months post-index health plan eligibility. 
Adherence was measured using medication possession ratio (MPR). Multivariate 
negative binomial regression was used to estimate association between study cohorts 
and one-year post-index cardiovascular disease (CVD)-related THR (sum of emer-
gency room, inpatient, and outpatient visits) after controlling for differences in base-
line age, gender, THR, Deyo-Charlson comorbidity index (DCI) score, number of 
non-dyslipidemia medications, and post-index adherence. RESULTS: Among study 
patients [8988 patients (6638 FDC; 1687 NER/S; 663 NER/L)], those initiating FDC 
therapy were signiﬁ cantly younger [mean (SD) ages of 51.9 (10.5) vs. 56.0 (9.8) years,
p  0.0001], comprised of fewer males (73.0% vs. 81.5%; p  0.0001), and had sig-
niﬁ cantly lower baseline DCI scores (0.43 o 0.88 vs. 0.59 o 1.06; p  0.0001) versus
MPC patients. During one-year follow-up, average MPR was higher among FDC
patients versus both NER/S and NER/L patients (0.54 o 0.35 vs. 0.50 o 0.35 and 0.47
o 0.34, respectively; p  0.01). Controlling for post-index adherence, multivariate
regression demonstrated that FDC patients had an 18% decrease in annual CVD-
related THR versus MPC patients [IRR: 0.819, 95% CI: 0.761–0.882); p  0.0001]. 
CONCLUSIONS: FDC-initiated patients showed improved medication adherence and
reduced CVD-related THR versus MPC-initiated patients in this managed care popula-
tion. Further studies on clinical and economic impact of improved adherence to FDC
dyslipidemia therapy are warranted.
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MEASURING THE IMPACT OF SOCIO-DEMOGRAPHIC
CHARACTERISTICS ON PATIENT PERSISTENCE IN CHRONIC MARKETS
Henderson SC1, Denarie MF2, Yuan Y1
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OBJECTIVES: Although patient ﬁ nances are widely studied as predictors of adherence,
claims databases rarely include variables other than copay and insurance coverage.
Linking personal income, level of education, and ethnicity to prescription data can
enhance analyses of socioeconomic factors and adherence. We compared persistence 
in chronic markets – statins and oral antidiabetics (OADs) – by income, education, 
and ethnicity in linked administrative databases. METHODS: Using IMS’ LifeLink 
longitudinal prescription database (LRx), linked to commercial socio-economic data, 
we selected 143,370 patients initiating statins and 57,079 patients initiating OADs 
after a minimum 12 month clean period. LRx captures 62% of prescription claims
contributed by retail pharmacies in the US. Cox proportional hazards models compared
persistence by income, education, ethnicity, age, and method of payment. RESULTS:
Mean days of statin persistence was higher for patients with household income 
$75K/yr (149 days) than for patients with $40–75,000K/year household income
(144 days) (p  0.001). Patients with very low income ($K/yr) were more frequently 
on Medicaid or over age 65; these very low income patients had higher persistence
(150 days) than patients with income of $15$40,000/year (144 days) (p  0.005). 
Persistence also increased with level of education (graduate school  154 days vs. high 
school  147 days, p  0.001) and differed by ethnicity (Caucasian  150 days, Hispanic 
 127 days, African American  124 days; p  0.001). Similar trends were observed 
with OADs. CONCLUSIONS: Patients with higher household income demonstrate 
slightly improved persistence, while patients with very low income, but subsidized 
pharmacy beneﬁ ts, also have higher than average persistence. Differences in persistence 
also are found with higher levels of education and across ethnic groups.
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FRACTION OF NURSING HOME ADMISSION AND INCREMENTAL COST
ATTRIBUTABLE TO NON ADHERENCE TO ANTI HYPERTENSIVE 
MEDICATIONS
Rapp T, Schneider M, Zuckerman IH
University of Maryland, Baltimore, MD, USA
OBJECTIVES: We estimated the relationship between nursing home admission and 
non-adherence to anti-hypertensive medications. We calculated the incremental 
proportion of nursing home admission that was due to non-adherence, and the
annual incremental cost of the proportion of nursing home admission due to non-
adherence. METHODS: We calculated adherence scores in a cohort of 225,624 sub-
jects with hypertension from the MarketScan database. We used a generalized linear 
model with a binomial distribution and a log link to estimate adjusted relative risks
of nursing home admission. We calculated the fraction of nursing home admission
attributable to non-adherence. RESULTS: We showed that non-adherence to anti-
hypertensive medications increases the risk of nursing home admission. Among non-
adherent subjects, 10.8% were admitted to nursing homes. In the general population
of community-dwelling elderly subjects, 1.9% of nursing home admissions were 
attributable to non-adherence to anti-hypertensive medication. Extending these results
to the United States elderly (age q 65) population with hypertension, we found that 
annually 28,372 subjects were admitted to nursing homes in 2002 because of non-
adherence to anti-hypertensive medications. In 2002, the cost of nursing home admis-
sion due to non-adherence was estimated to be $1.7 billion. CONCLUSIONS:
Anti-hypertensive medication non-adherence was a risk factor for elderly transitioning
to long-term care facilities. Since non-adherence may be viewed as a proxy for lack 
of social support, our results show the potential beneﬁ ts related to interventions that
could provide social support to elderly patients, such as assistance with medication 
administration.
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OBJECTIVES: Poor adherence to anti-hypertensives severely compromises the effec-
tiveness of treatment. The aim of this study was to measure adherence to antihyper-
tensive therapy and to determine the factors that are associated with poor adherence
in a sample of hypertensive patients in Nsukka, a semi urban town located in South-
Eastern Nigeria. METHODS: A cross sectional, household survey was conducted in
Nsukka. Adherence to antihypertensive medications was assessed on participants that
were hypertensive. Patient self-reports about the number of pills taken over a pre-
scribed period were used to estimate adherence as a percentage. In addition, Morisky 
Medication Adherence Scale (MMAS) was used in order to increase the strength and 
consistency of patient’s self-report on adherence. RESULTS: A total of 756 partici-
pants were screened for hypertension. Forty-seven persons were hypertensive. Mean 
adherence to hypertension medication was 70.7% o 37.9%. Mean adherence score 
was correlated to MMAS score (r  0.401, p  0.05). Educational status, making 
medications a habit, and experience of side effects were independently correlated to
adherence. Multiple linear regression showed that for every increase in educational 
status, adherence increased by 12.1%. Also making medication a habit increased 
adherence by 35.09%. However, experience of side-effect decreased adherence by
20.1%. CONCLUSIONS: These factors identiﬁ ed as correlates of adherence to anti-
hypertensives in the study population could be used to design interventions to improve 
adherence to hypertension medications in Nigeria.
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FLUSHING ASSESSMENT TOOL (FAST): PSYCHOMETRIC PROPERTIES
OF A NEW MEASURE ASSESSING FLUSHING SYMPTOMS
Kawata AK1, Thakkar R2, Davidson MH3, Punzi HA4, Jiang P2, Li D2, Krause S2, Padley R2, 
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OBJECTIVES: A common side effect of niacin therapy is ﬂ ushing characterized by 
warmth, redness, itching, and/or tingling. The FAST was developed to assess ﬂ ushing 
symptoms and clinical impact on patients. This study evaluated the psychometrics and
minimal important difference (MID) of the FAST. METHODS: A randomized, double-
blind, parallel group, multicenter, placebo (PBO)-controlled prospective 6-week study 
evaluated the FAST. 269 patients with dyslipidemia were randomized (1:1:1) to niacin 
extended-release (NER)/acetylsalicylic acid (ASA), NER/ASA PBO, or PBO/PBO. 
Patients completed the FAST electronic diary daily. RESULTS: FAST test-retest reli-
ability during the ﬁ rst 2 weeks among stable subjects was demonstrated for mean
overall ﬂ ushing severity using patient/physician-rated overall treatment effect (OTE) 
ratings (intraclass correlation coefﬁ cients of 0.75 and 0.76). Over the 6 week treatment
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period, FAST scores were signiﬁ cantly correlated with individual symptoms, impact
on daily activities and sleep, and ﬂ ushing-related dissatisfaction (p  0.01). Changes 
in FAST scores were associated with treatment satisfaction (p  0.01) and patient/phy-
sician-rated OTE (p  0.01). Responders, deﬁ ned by improved OTE ratings, experi-
enced greater improvements than non-responders (p  0.01) in maximum (1.85 points 
vs. 0.18 points) and mean (0.51 points vs. 0.15 points) overall ﬂ ushing severity
scores. Among patients with ﬂ ushing, mean FAST scores differed between those who 
subsequently discontinued due to ﬂ ushing (7.9/10 points) vs. those who did not (4.7/10
points; p  0.001). The probable range in this study for a detectable change in ﬂ ushing 
symptoms (MID) was 0.29–0.38 points for mean overall ﬂ ushing severity and 0.41–
0.54 points for maximum overall ﬂ ushing severity. CONCLUSIONS: The FAST is a
new instrument designed to assess the symptoms and impact of niacin-induced ﬂ ush-
ing. The FAST exhibited test-retest reliability and substantial evidence of construct 
validity among patients with dyslipidemia. Overall, ﬂ ushing severity was responsive 
to change over time, suggesting that the FAST is a useful instrument for evaluating
ﬂ ushing symptoms induced by niacin therapy.
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IS MEASURING HEALTH STATUS BENEFICIAL IN HEART FAILURE
PATIENTS?
Höfer S1, Frick M1, Pölzl G1, Benzer W2
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Austria
OBJECTIVES: Measuring patients subjective health status (HS) has become accepted
in cardiology. However, the effect of these measurements on outcome and well-being
of heart failure patients remains unclear. METHODS: The aim of this study was to
investigate the impact of measuring HS on intermediate patients’ well-being. In two
Austrian heart failure outpatient wards 175 patients with documented heart failure 
were randomized into an intervention (IG) and control group (CG). Patients HS in
the IG was measured prior to the physician contact using the Short-Form 36 and 
Hospital Anxiety and Depression Scale. IG-patients received feedback electronically
feedback on their individual HS. The results were also made available to the treating 
physicians. They were encouraged to give additional feedback or to apply results for
auxiliary treatment planning (e.g., counselling). Patients in CG received usual care
without measuring HS prior to the physicians visit. After the visit, patients in both
groups rated their health-related quality of life (HRQL) and general health on the 
MacNew Heart Disease HRQL Instrument. Patients were reassessed by postal ques-
tionnaire six months after initial visit. RESULTS: Complete 6-month follow-up data
was available for 139 patients (79% response rate; 25.3% female; age: 58 o 13.2;
64.2% retired; NYHA I: 14.7%, NYHA II: 53.9%, NYHA III: 24.5%, NYHA IV: 
6.9%). Physical HRQL signiﬁ cantly deteriorated in both groups (IG: 0.3; CG: 0.4, 
both p  .01), whereas no signiﬁ cant deterioration for emotional and social HRQL 
was reported by the IG (IG: 0.1; 0.1, p  ns). Overall health improved in 34% of 
the IG patients, but only in 22% of the CG patients [ARR  12%, p  0.09; NNT of 
9]. CONCLUSIONS: Routine assessment of patients subjective HS appears to be
beneﬁ cial in helping maintain the well-being of heart failure patients (NNT  9), which 
naturally decreases over time. These results, however, need to be replicated in an ade-
quately powered study [N  211,á  .005, 1-â  0.89].
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EVALUATION OF COMPARATIVE EFFECTIVENESS: A MODEL FOR
GENERATING HYPOTHESES AND DETERMINING SAMPLE SIZE
Bharmal M1, Cascade EF2, Gemmen EK1
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OBJECTIVES: Although payers are asking for comparative effectiveness data, risk of 
conducting studies is signiﬁ cant. One possible intermediary step is to leverage a vali-
dated instrument, the Treatment Satisfaction Questionnaire for Medication Version 
1.4 (TSQM), to identify domains for separation and calculate sample size required for 
superiority in a comparative study. METHODS: We used data from iGuard.org, a
consumer drug safety service totaling over 1 million members, whereby patients are
randomly invited to complete the TSQM on an on-going basis. TSQM is a 14-item 
reliable and valid instrument providing scores on four scales—effectiveness, side 
effects, convenience and global satisfaction. For this study, we analyzed all responses 
from patients using lisinopril and metoprolol. For sample size evaluation, adjusted 
means (LsMean) and standard errors (SE) were generated for each treatment using an 
analysis of covariance model controlling for: patient age; gender; self-reported severity 
of disease; and use of other hypertensive, diabetes and heart failure medications.
RESULTS: A total of 625 patients, 363 (58.1%) on lisinopril and 262 (41.9%) on 
metoprolol completed the TSQM between March and November 2008. TSQM
domains had good internal consistency with Cronbach’s alpha values over 0.85. There
were signiﬁ cant differences between the two treatments on age; self-reported severity; 
and use of diabetes and heart failure medications. LsMean (SE) for lisinopril and
metoprolol was 68.80 (1.46) and 66.01 (1.53) on effectiveness; 90.72 (1.83) and 85.66 
(1.91) on side effects; 87.09 (1.28) and 81.55 (1.34) on convenience; and 67.67 (1.78) 
and 62.92 (1.86) on global satisfaction, respectively. Given differences observed, a 
sample size of 640 per treatment would be required to detect a statistically signiﬁ cant
difference at a two-sided alpha of 0.05 with 80% power. CONCLUSIONS: This 
obtains feedback on comparative effectiveness study design and risk by conducting a
pre-study that administers a validated instrument to an on-line community.
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DIABETES MANAGEMENT AND KNOWLEDGE IMPROVEMENTS AS A 
RESULT OF PATIENT EDUCATION: A COMMUNITY BASED, 
RANDOMIZED CLINICAL TRIAL
Winston RA1, Lu Z2, Shaya FT2, Laird A1, Saunders E3
1Bon Secours Baltimore Health System, Baltimore, MD, USA, 2University of Maryland School
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MD, USA
OBJECTIVES: The purpose of this study is to assess: 1) the impact of different educa-
tion modules (class education, mail education or both) on Hemoglobin A1c control 
in diabetic patients with hypertension; 2) determine which education module was the
most effective for patient disease process awareness based on Knowledge Tool Test
scores. METHODS: Adult patients with type-2 Diabetes with concomitant hyperten-
sion were recruited from community based primary care physician ofﬁ ces. The study 
was composed of 825 diabetic patients, a subset of those enrolled in the Baltimore 
Partnership Programs to Reduce CVD Disparities project based on a minimum of one 
year of follow-up. Intervention patients received education either by class, mail, or 
both. HbA1c was measured at baseline and patients were followed-up every six 
months. Multiple regression models were used to assess the effects of 1) Different 
education modules on HbA1c change, deﬁ ned as percent change of HbA1c from
baseline; 2) different education modules on change of patients’ disease process aware-
ness, deﬁ ned as change of Knowledge Tool Test score from the baseline. The model
was adjusted for sociodemographic variables. RESULTS: The majority of the diabetic 
patients were African American (88.61%), females (65.62%), and the mean age was
65 years. The mean HbA1c reduction was 0.8. As compared to the control patients 
(0.7), the HbA1c reduction was larger in intervention patients (0.9). Males (0.82 
vs. 0.78) had a higher reduction in HbA1c values than females. Opposite trends were
found on patient disease process awareness. CONCLUSIONS: In this patient sample,
decreased trend in HbA1c level and an increased trend in Knowledge Tool Test score 
is seen among intervention patients, with class education module being more effective 
in patient disease process awareness. These results may help guide future patient
intervention programs for diabetes and hypertension management.
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PHARMACEUTICAL SPENDING ON CHRONIC DISEASES IN
CONSUMER DIRECTED HEALTH PLANS
Kadiyala S1, Mullainathan S2, Spackman DE1
1University of Washington, Seattle, WA, USA, 2Harvard University, Cambridge, MA, USA
OBJECTIVES: Consumer directed health plans (CDHP) are aimed at reducing moral
hazard due to insurance coverage. How do CDHP plans affect the consumption of 
pharmaceuticals for chronic diseases such as hypertension, high cholesterol and
diabetes? METHODS: We obtained data on all employees from a large private U.S.
employer for the 2005 to 2007 time period. All enrollees in the CDHP plan in this 
study are initially provided an employer funded Health Reimbursement Account 
(HRA) from which they can purchase medical care. Funds in these accounts range
from $1000 to $2000 depending on whether the enrollee is in an individual or a family 
health plan. After the HRA funds are exhausted, there is a second phase in which 
enrollee spending is completely out of pocket (range from $500 to $2000), after which
time the insurance plan begins coverage. We compare average daily pharmaceutical 
spending for individuals with diabetes, hypertension and high cholesterol as they move
through each of the different coverage thresholds(HRA, Out-of-Pocket and Full-
Coverage). RESULTS: Using Icd-9 codes we identiﬁ ed 27,644 individuals diagnosed
with diabetes, hypertension or high-cholesterol. For each of these diseases average 
daily pharmaceutical expenditure was substantially lower when individuals were in
the HRA and out-of-pocket sections of their CDHP plan as compared to when they 
were in the Full-Coverage part of their insurance plan. Average daily expenditure on 
pharmaceuticals was approximately $2.60 for individuals in the HRA section of the 
plan, $1.00 for individuals who moved into the out-of-pocket part of the insurance 
plan and $4.00 for individuals who were covered by insurance. CONCLUSIONS:
Findings from this study suggest that cost-sharing levels in CDHP plans affect phar-
maceutical spending on the treatment of chronic diseases. Reductions in chronic
disease pharmaceutical expenditures have the potential to negatively affect enrollee
health outcomes.
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DISPARITIES IN CORONARY ARTERY DISEASE CARE AMONG
ENROLLEES WITH AARP MEDICARE SUPPLEMENT INSURANCE
Hawkins K1, Escoto KH2, Ozminkowski RJ3, Bhattarai GR4, Marshall JK5, Harbin HT6, 
Migliori RM7
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OBJECTIVES: Discover if age-, gender-, race-, or income-related disparities in care 
for coronary artery disease (CAD) exist among Medicare enrollees with supplement 
plan coverage (i.e. Medigap). METHODS: Data were obtained from UnitedHealth
Group’s database of AARP Medigap enrollees. Patients were selected into the study 
if they had one or more medical claims with a diagnosis of CAD from July 1, 2006-
June 30, 2007. Logistic regression analyses tested for age-, gender-, race-, or income-
related differences in the likelihood of receiving an ofﬁ ce visit, coronary angiography,
or surgical intervention. The regression models controlled for socioeconomics, health 
